Low‐dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor‐titer below 200 BU/mL

Documenti analoghi

• Thrombotic microangiopathy associated with calcineurin inhibitor induction doses in patients with a kidney transplant
  di: Alfredo Gutiérrez‐Govea, et al.
  Pubblicazione: (2024)
• Systemic lupus erythematosus caused acquired hemophilia B without evidence of factor IX inhibitors
  di: Lifang Wang, et al.
  Pubblicazione: (2025)
• Discovery and optimization of 3‐(indolin‐5‐yloxy)pyridin‐2‐amine derivatives as potent necroptosis inhibitors
  di: Yaohan Lan, et al.
  Pubblicazione: (2024)
• Emicizumab for acquired hemophilia A: Report of two cases and dosing strategies
  di: Faiza Ahmed, et al.
  Pubblicazione: (2024)
• Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus
  di: Jiazhou Li, et al.
  Pubblicazione: (2024)